• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用患者来源的骨髓成骨祖细胞对黏多糖贮积症Ⅰ型进行骨骼发育不良建模。

Modeling skeletal dysplasia in Hurler syndrome using patient-derived bone marrow osteoprogenitor cells.

机构信息

Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.

Tettamanti Center, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.

出版信息

JCI Insight. 2024 Mar 8;9(5):e173449. doi: 10.1172/jci.insight.173449.

DOI:10.1172/jci.insight.173449
PMID:38456506
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10972592/
Abstract

Dysostosis multiplex is a major cause of morbidity in Hurler syndrome (mucopolysaccharidosis type IH [MPS IH], OMIM #607014) because currently available therapies have limited success in its prevention and reversion. Unfortunately, the elucidation of skeletal pathogenesis in MPS IH is limited by difficulties in obtaining bone specimens from pediatric patients and poor reproducibility in animal models. Thus, the application of experimental systems that can be used to dissect cellular and molecular mechanisms underlying the skeletal phenotype of MPS IH patients and to identify effective therapies is highly needed. Here, we adopted in vitro/in vivo systems based on patient-derived bone marrow stromal cells to generate cartilaginous pellets and bone rudiments. Interestingly, we observed that heparan sulphate accumulation compromised the remodeling of MPS IH cartilage into other skeletal tissues and other critical aspects of the endochondral ossification process. We also noticed that MPS IH hypertrophic cartilage was characterized by dysregulation of signaling pathways controlling cartilage hypertrophy and fate, extracellular matrix organization, and glycosaminoglycan metabolism. Our study demonstrates that the cartilaginous pellet-based system is a valuable tool to study MPS IH dysostosis and to develop new therapeutic approaches for this hard-to-treat aspect of the disease. Finally, our approach may be applied for modeling other genetic skeletal disorders.

摘要

多发性骨发育不良是黏多糖贮积症 I 型(Hurler 综合征,MPS IH,OMIM #607014)患者发病和致残的主要原因,因为目前可用的治疗方法在预防和逆转方面效果有限。不幸的是,由于难以从儿科患者中获得骨骼标本以及动物模型的重现性差,MPS IH 骨骼发病机制的阐明受到限制。因此,迫切需要应用能够剖析 MPS IH 患者骨骼表型的细胞和分子机制并确定有效治疗方法的实验系统。在这里,我们采用了基于患者来源的骨髓基质细胞的体外/体内系统来生成软骨小球和骨原基。有趣的是,我们观察到硫酸乙酰肝素的积累会损害 MPS IH 软骨向其他骨骼组织以及软骨内化骨过程的其他关键方面的重塑。我们还注意到,MPS IH 肥大软骨的特征是控制软骨肥大和命运、细胞外基质组织和糖胺聚糖代谢的信号通路失调。我们的研究表明,基于软骨小球的系统是研究 MPS IH 多发性骨发育不良的有用工具,并为这种难以治疗的疾病方面开发新的治疗方法。最后,我们的方法可用于模拟其他遗传性骨骼疾病。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f65/10972592/0afc78361d3e/jciinsight-9-173449-g133.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f65/10972592/2a2cf27587b4/jciinsight-9-173449-g125.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f65/10972592/fa17f7b6665f/jciinsight-9-173449-g126.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f65/10972592/3178c466fe7a/jciinsight-9-173449-g127.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f65/10972592/59980d72f24b/jciinsight-9-173449-g128.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f65/10972592/fc2ee56b2af9/jciinsight-9-173449-g129.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f65/10972592/2e585af85246/jciinsight-9-173449-g130.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f65/10972592/1b50f7b975bf/jciinsight-9-173449-g131.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f65/10972592/46e374c4f03e/jciinsight-9-173449-g132.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f65/10972592/0afc78361d3e/jciinsight-9-173449-g133.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f65/10972592/2a2cf27587b4/jciinsight-9-173449-g125.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f65/10972592/fa17f7b6665f/jciinsight-9-173449-g126.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f65/10972592/3178c466fe7a/jciinsight-9-173449-g127.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f65/10972592/59980d72f24b/jciinsight-9-173449-g128.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f65/10972592/fc2ee56b2af9/jciinsight-9-173449-g129.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f65/10972592/2e585af85246/jciinsight-9-173449-g130.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f65/10972592/1b50f7b975bf/jciinsight-9-173449-g131.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f65/10972592/46e374c4f03e/jciinsight-9-173449-g132.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f65/10972592/0afc78361d3e/jciinsight-9-173449-g133.jpg

相似文献

1
Modeling skeletal dysplasia in Hurler syndrome using patient-derived bone marrow osteoprogenitor cells.利用患者来源的骨髓成骨祖细胞对黏多糖贮积症Ⅰ型进行骨骼发育不良建模。
JCI Insight. 2024 Mar 8;9(5):e173449. doi: 10.1172/jci.insight.173449.
2
Mucopolysaccharidosis Type II型粘多糖贮积症
3
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
4
Alterations in Hurler-Scheie Syndrome Revealed by Mass Spectrometry-Based Proteomics and Phosphoproteomics Analysis.基于质谱的蛋白质组学和磷酸化蛋白质组学分析揭示的 Hurler-Scheie 综合征的改变。
OMICS. 2024 Nov;28(11):548-562. doi: 10.1089/omi.2024.0171. Epub 2024 Oct 29.
5
Enzyme replacement therapy with laronidase (Aldurazyme(®)) for treating mucopolysaccharidosis type I.用拉罗尼酶(阿糖苷酶α(Aldurazyme(®)))进行酶替代疗法治疗I型黏多糖贮积症。
Cochrane Database Syst Rev. 2016 Apr 1;4:CD009354. doi: 10.1002/14651858.CD009354.pub4.
6
Enzyme replacement therapy with laronidase (Aldurazyme(®)) for treating mucopolysaccharidosis type I.用拉罗尼酶(阿糖苷酶α(商品名:Aldurazyme(®)))进行酶替代疗法治疗I型黏多糖贮积症。
Cochrane Database Syst Rev. 2013 Nov 21(11):CD009354. doi: 10.1002/14651858.CD009354.pub3.
7
Natural history of craniovertebral abnormalities in a single-center study in 54 patients with Hurler syndrome.54 例黏多糖贮积症患者单中心研究中的颅颈畸形自然史。
J Neurosurg Pediatr. 2024 Mar 15;33(6):574-582. doi: 10.3171/2024.1.PEDS23281. Print 2024 Jun 1.
8
Enzyme replacement therapy with laronidase (Aldurazyme) for treating mucopolysaccharidosis type I.用拉罗尼酶(阿糖苷酶α)进行酶替代疗法治疗I型黏多糖贮积症。
Cochrane Database Syst Rev. 2013 Sep 26(9):CD009354. doi: 10.1002/14651858.CD009354.pub2.
9
A New Measure of Quantified Social Health Is Associated With Levels of Discomfort, Capability, and Mental and General Health Among Patients Seeking Musculoskeletal Specialty Care.一种新的量化社会健康指标与寻求肌肉骨骼专科护理的患者的不适程度、能力以及心理和总体健康水平相关。
Clin Orthop Relat Res. 2025 Apr 1;483(4):647-663. doi: 10.1097/CORR.0000000000003394. Epub 2025 Feb 5.
10
Neonatal nonviral gene editing with the CRISPR/Cas9 system improves some cardiovascular, respiratory, and bone disease features of the mucopolysaccharidosis I phenotype in mice.CRISPR/Cas9 系统对新生鼠的非病毒基因编辑可改善黏多糖贮积症 I 表型的一些心血管、呼吸和骨骼疾病特征。
Gene Ther. 2020 Feb;27(1-2):74-84. doi: 10.1038/s41434-019-0113-4. Epub 2019 Dec 11.

引用本文的文献

1
Neonatal gene therapy effectively prevents disease manifestations in a murine model of Mucopolysaccharidosis type I.新生儿基因疗法可有效预防I型黏多糖贮积症小鼠模型中的疾病表现。
Mol Ther Methods Clin Dev. 2025 Jul 30;33(3):101544. doi: 10.1016/j.omtm.2025.101544. eCollection 2025 Sep 11.

本文引用的文献

1
An humanized model to study homing and sequestration of transmission stages in the bone marrow.一种用于研究骨髓中传播阶段归巢和隔离的人源化模型。
Front Cell Infect Microbiol. 2023 Apr 19;13:1161669. doi: 10.3389/fcimb.2023.1161669. eCollection 2023.
2
Long term follow-up after haematopoietic stem cell transplantation for mucopolysaccharidosis type I-H: a retrospective study of 51 patients.黏多糖贮积症 I-H 型患者造血干细胞移植后的长期随访:51 例回顾性研究。
Bone Marrow Transplant. 2023 Mar;58(3):295-302. doi: 10.1038/s41409-022-01886-1. Epub 2022 Dec 9.
3
MPSI Manifestations and Treatment Outcome: Skeletal Focus.
MPSI 表现与治疗结局:骨骼病灶。
Int J Mol Sci. 2022 Sep 22;23(19):11168. doi: 10.3390/ijms231911168.
4
Effects of lithium administration on vertebral bone disease in mucopolysaccharidosis I dogs.锂剂治疗对黏多糖贮积症 I 型犬的椎骨疾病的影响。
Bone. 2022 Jan;154:116237. doi: 10.1016/j.bone.2021.116237. Epub 2021 Oct 22.
5
From Stem Cells to Bone-Forming Cells.从干细胞到成骨细胞。
Int J Mol Sci. 2021 Apr 13;22(8):3989. doi: 10.3390/ijms22083989.
6
SOX9 keeps growth plates and articular cartilage healthy by inhibiting chondrocyte dedifferentiation/osteoblastic redifferentiation.SOX9 通过抑制软骨细胞去分化/成骨细胞再分化来保持生长板和关节软骨的健康。
Proc Natl Acad Sci U S A. 2021 Feb 23;118(8). doi: 10.1073/pnas.2019152118.
7
Twelve years of SAMtools and BCFtools.SAMtools 和 BCFtools 十二年。
Gigascience. 2021 Feb 16;10(2). doi: 10.1093/gigascience/giab008.
8
Failures of Endochondral Ossification in the Mucopolysaccharidoses.黏多糖贮积症中的软骨内骨化失败。
Curr Osteoporos Rep. 2020 Dec;18(6):759-773. doi: 10.1007/s11914-020-00626-y. Epub 2020 Oct 16.
9
Mucopolysaccharidosis Type I: A Review of the Natural History and Molecular Pathology.黏多糖贮积症 I 型:自然病史和分子病理学综述。
Cells. 2020 Aug 5;9(8):1838. doi: 10.3390/cells9081838.
10
IRX3 and IRX5 Inhibit Adipogenic Differentiation of Hypertrophic Chondrocytes and Promote Osteogenesis.IRX3和IRX5抑制肥大软骨细胞的脂肪生成分化并促进骨生成。
J Bone Miner Res. 2020 Dec;35(12):2444-2457. doi: 10.1002/jbmr.4132. Epub 2020 Aug 17.